diff --git "a/dev_JRCT_api/vector_search.ipynb" "b/dev_JRCT_api/vector_search.ipynb"
new file mode 100644--- /dev/null
+++ "b/dev_JRCT_api/vector_search.ipynb"
@@ -0,0 +1,2368 @@
+{
+ "cells": [
+  {
+   "cell_type": "code",
+   "execution_count": 86,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "from sentence_transformers import SentenceTransformer, util\n",
+    "import pandas as pd\n",
+    "import re"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 87,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Target列を分割する関数\n",
+    "def split_target(target):\n",
+    "    # 指定された区切り文字で分割\n",
+    "    split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n",
+    "    # 空白文字を除外してリストとして返す\n",
+    "    return [word.strip() for word in split_words if word.strip()]"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 88,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241202Cancer.csv', index_col=0)\n",
+    "basedf = basedf.dropna(subset=['試験等のフェーズ'])\n",
+    "# Target列を分割してTargetWord列を追加\n",
+    "basedf['TargetWord'] = basedf['Target'].apply(split_target)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 84,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>JRCT ID</th>\n",
+       "      <th>NCT No</th>\n",
+       "      <th>JapicCTI No</th>\n",
+       "      <th>Title</th>\n",
+       "      <th>Target</th>\n",
+       "      <th>研究・治験の目的</th>\n",
+       "      <th>試験等のフェーズ</th>\n",
+       "      <th>試験の種類</th>\n",
+       "      <th>無作為化</th>\n",
+       "      <th>盲検化</th>\n",
+       "      <th>...</th>\n",
+       "      <th>purpose</th>\n",
+       "      <th>Inclusion Criteria</th>\n",
+       "      <th>Exclusion Criteria</th>\n",
+       "      <th>Age Minimum</th>\n",
+       "      <th>Age Maximum</th>\n",
+       "      <th>Gender</th>\n",
+       "      <th>Discontinuation Criteria</th>\n",
+       "      <th>Keyword</th>\n",
+       "      <th>Intervention(s)</th>\n",
+       "      <th>TargetWord</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>jRCT2021240039</td>\n",
+       "      <td>NCT06632951</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>[M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal...</td>\n",
+       "      <td>尿路上皮癌</td>\n",
+       "      <td>主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Participant has histologically or cytological...</td>\n",
+       "      <td>-Participant has received more than 1 prior ch...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r...</td>\n",
+       "      <td>[尿路上皮癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>4</th>\n",
+       "      <td>jRCT2031240512</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>フッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌...</td>\n",
+       "      <td>切除不能進行・再発胃癌</td>\n",
+       "      <td>フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor...</td>\n",
+       "      <td>1)\\tPrior treatment history with paclitaxel, r...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>75age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Safety Part (Dose Escalation):\\r\\nLevel 0: Bev...</td>\n",
+       "      <td>[切除不能進行, 再発胃癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>7</th>\n",
+       "      <td>jRCT2051240197</td>\n",
+       "      <td>NCT06692738</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>PD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto...</td>\n",
+       "      <td>非小細胞肺癌</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>二重盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Histologically or cytologically documented s...</td>\n",
+       "      <td>- Presence of small cell and neuroendocrine hi...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Participants will be randomized in a 1:1 ratio...</td>\n",
+       "      <td>[非小細胞肺癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>8</th>\n",
+       "      <td>jRCT2031240508</td>\n",
+       "      <td>NCT06573294</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用...</td>\n",
+       "      <td>進行性悪性固形癌\\n転移性悪性固形癌</td>\n",
+       "      <td>本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Advanced and/or metastatic solid tumors, who ...</td>\n",
+       "      <td>Has been exposed to any of the following prior...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>GEN1057 monotherapy will be administered intra...</td>\n",
+       "      <td>[進行性悪性固形癌, 転移性悪性固形癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>12</th>\n",
+       "      <td>jRCT2041240130</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...</td>\n",
+       "      <td>肺がん</td>\n",
+       "      <td>全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(1) Patients scheduled to undergo anatomical l...</td>\n",
+       "      <td>(1) Patients with a history of allergy to the ...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Treatment group\\r\\nAdminister GRA 1mg intraven...</td>\n",
+       "      <td>[肺がん]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>...</th>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>974</th>\n",
+       "      <td>jRCT2031200203</td>\n",
+       "      <td>NCT04379596</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>HER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法...</td>\n",
+       "      <td>胃腺癌、胃食道接合部腺癌又は食道腺癌</td>\n",
+       "      <td>DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Male and female participants must be at lea...</td>\n",
+       "      <td>1. History of active primary immunodeficiency,...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>130age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Experimental: Arm 1A: T-DXd and 5-fluorouracil...</td>\n",
+       "      <td>[胃腺癌, 胃食道接合部腺癌, 食道腺癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>981</th>\n",
+       "      <td>jRCT2031200153</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Cellm-001による初発膠芽腫治療効果無作為比較対照試験</td>\n",
+       "      <td>膠芽腫</td>\n",
+       "      <td>脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>二重盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(1) 18 years old or older and 75 years old or ...</td>\n",
+       "      <td>(1) Systemic administration of corticosteroids...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>75age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Inject the investigational drug (Cellm-001 or ...</td>\n",
+       "      <td>[膠芽腫]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>996</th>\n",
+       "      <td>jRCT2031200087</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療...</td>\n",
+       "      <td>4型進行胃癌</td>\n",
+       "      <td>術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Confirmation before temporary registration\\r\\n...</td>\n",
+       "      <td>1)\\tSimultaneously active double cancer.\\r\\n2)...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>75age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>S-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da...</td>\n",
+       "      <td>[4型進行胃癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>1053</th>\n",
+       "      <td>jRCT2033190086</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...</td>\n",
+       "      <td>悪性黒色腫</td>\n",
+       "      <td>第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(Phase 1)\\r\\n1) Histologically confirmed malig...</td>\n",
+       "      <td>(Phase 1 and 2)\\r\\n1) Patients who have brain ...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>malignamt  melanoma, advanced stage</td>\n",
+       "      <td>Test drug (T-hIL12) will be administered into ...</td>\n",
+       "      <td>[悪性黒色腫]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>1067</th>\n",
+       "      <td>jRCT2051190009</td>\n",
+       "      <td>NCT03818893</td>\n",
+       "      <td>JapicCTI-194618</td>\n",
+       "      <td>進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...</td>\n",
+       "      <td>進行性悪性黒色腫</td>\n",
+       "      <td>抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>非無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Inclusion criteria \\r\\nPatients meeting all of...</td>\n",
+       "      <td>Exclusion criteria\\r\\nPatients meeting any of ...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>86age old not</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>advanced melanoma</td>\n",
+       "      <td>combination therapy of intracutaneous GEN0101 ...</td>\n",
+       "      <td>[進行性悪性黒色腫]</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>416 rows × 39 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "             JRCT ID       NCT No      JapicCTI No  \\\n",
+       "0     jRCT2021240039  NCT06632951              NaN   \n",
+       "4     jRCT2031240512          NaN              NaN   \n",
+       "7     jRCT2051240197  NCT06692738              NaN   \n",
+       "8     jRCT2031240508  NCT06573294              NaN   \n",
+       "12    jRCT2041240130          NaN              NaN   \n",
+       "...              ...          ...              ...   \n",
+       "974   jRCT2031200203  NCT04379596              NaN   \n",
+       "981   jRCT2031200153          NaN              NaN   \n",
+       "996   jRCT2031200087          NaN              NaN   \n",
+       "1053  jRCT2033190086          NaN              NaN   \n",
+       "1067  jRCT2051190009  NCT03818893  JapicCTI-194618   \n",
+       "\n",
+       "                                                  Title              Target  \\\n",
+       "0     [M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal...               尿路上皮癌   \n",
+       "4     フッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌...         切除不能進行・再発胃癌   \n",
+       "7     PD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto...              非小細胞肺癌   \n",
+       "8     悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用...  進行性悪性固形癌\\n転移性悪性固形癌   \n",
+       "12    中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...                 肺がん   \n",
+       "...                                                 ...                 ...   \n",
+       "974   HER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法...  胃腺癌、胃食道接合部腺癌又は食道腺癌   \n",
+       "981                      Cellm-001による初発膠芽腫治療効果無作為比較対照試験                 膠芽腫   \n",
+       "996   4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療...              4型進行胃癌   \n",
+       "1053  悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...               悪性黒色腫   \n",
+       "1067  進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...            進行性悪性黒色腫   \n",
+       "\n",
+       "                                               研究・治験の目的 試験等のフェーズ 試験の種類  \\\n",
+       "0     主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig...        2   NaN   \n",
+       "4     フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ...        1   NaN   \n",
+       "7                                             Treatment        3   NaN   \n",
+       "8     本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単...        1   NaN   \n",
+       "12    全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...        2   NaN   \n",
+       "...                                                 ...      ...   ...   \n",
+       "974   DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）...      1-2   NaN   \n",
+       "981   脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...        3   NaN   \n",
+       "996   術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に...        3   NaN   \n",
+       "1053  第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...      1-2   NaN   \n",
+       "1067  抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...      1-2   NaN   \n",
+       "\n",
+       "         無作為化   盲検化  ...            purpose  \\\n",
+       "0      無作為化比較   非盲検  ...  treatment purpose   \n",
+       "4      無作為化比較   非盲検  ...  treatment purpose   \n",
+       "7      無作為化比較  二重盲検  ...  treatment purpose   \n",
+       "8         単一群   非盲検  ...  treatment purpose   \n",
+       "12     無作為化比較   非盲検  ...  treatment purpose   \n",
+       "...       ...   ...  ...                ...   \n",
+       "974    無作為化比較   非盲検  ...  treatment purpose   \n",
+       "981    無作為化比較  二重盲検  ...  treatment purpose   \n",
+       "996    無作為化比較   非盲検  ...  treatment purpose   \n",
+       "1053      単一群   非盲検  ...  treatment purpose   \n",
+       "1067  非無作為化比較   非盲検  ...  treatment purpose   \n",
+       "\n",
+       "                                     Inclusion Criteria  \\\n",
+       "0     -Participant has histologically or cytological...   \n",
+       "4     1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor...   \n",
+       "7     - Histologically or cytologically documented s...   \n",
+       "8     -Advanced and/or metastatic solid tumors, who ...   \n",
+       "12    (1) Patients scheduled to undergo anatomical l...   \n",
+       "...                                                 ...   \n",
+       "974   1. Male and female participants must be at lea...   \n",
+       "981   (1) 18 years old or older and 75 years old or ...   \n",
+       "996   Confirmation before temporary registration\\r\\n...   \n",
+       "1053  (Phase 1)\\r\\n1) Histologically confirmed malig...   \n",
+       "1067  Inclusion criteria \\r\\nPatients meeting all of...   \n",
+       "\n",
+       "                                     Exclusion Criteria     Age Minimum  \\\n",
+       "0     -Participant has received more than 1 prior ch...  18age old over   \n",
+       "4     1)\\tPrior treatment history with paclitaxel, r...  18age old over   \n",
+       "7     - Presence of small cell and neuroendocrine hi...  18age old over   \n",
+       "8     Has been exposed to any of the following prior...  18age old over   \n",
+       "12    (1) Patients with a history of allergy to the ...  18age old over   \n",
+       "...                                                 ...             ...   \n",
+       "974   1. History of active primary immunodeficiency,...  18age old over   \n",
+       "981   (1) Systemic administration of corticosteroids...  18age old over   \n",
+       "996   1)\\tSimultaneously active double cancer.\\r\\n2)...  20age old over   \n",
+       "1053  (Phase 1 and 2)\\r\\n1) Patients who have brain ...  20age old over   \n",
+       "1067  Exclusion criteria\\r\\nPatients meeting any of ...  20age old over   \n",
+       "\n",
+       "           Age Maximum Gender Discontinuation Criteria  \\\n",
+       "0             No limit   Both                      NaN   \n",
+       "4      75age old under   Both                      NaN   \n",
+       "7             No limit   Both                      NaN   \n",
+       "8             No limit   Both                      NaN   \n",
+       "12            No limit   Both                      NaN   \n",
+       "...                ...    ...                      ...   \n",
+       "974   130age old under   Both                      NaN   \n",
+       "981    75age old under   Both                      NaN   \n",
+       "996    75age old under   Both                      NaN   \n",
+       "1053          No limit   Both                      NaN   \n",
+       "1067     86age old not   Both                      NaN   \n",
+       "\n",
+       "                                  Keyword  \\\n",
+       "0                                     NaN   \n",
+       "4                                     NaN   \n",
+       "7                                     NaN   \n",
+       "8                                     NaN   \n",
+       "12                                    NaN   \n",
+       "...                                   ...   \n",
+       "974                                   NaN   \n",
+       "981                                   NaN   \n",
+       "996                                   NaN   \n",
+       "1053  malignamt  melanoma, advanced stage   \n",
+       "1067                    advanced melanoma   \n",
+       "\n",
+       "                                        Intervention(s)             TargetWord  \n",
+       "0     -Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r...                [尿路上皮癌]  \n",
+       "4     Safety Part (Dose Escalation):\\r\\nLevel 0: Bev...         [切除不能進行, 再発胃癌]  \n",
+       "7     Participants will be randomized in a 1:1 ratio...               [非小細胞肺癌]  \n",
+       "8     GEN1057 monotherapy will be administered intra...   [進行性悪性固形癌, 転移性悪性固形癌]  \n",
+       "12    Treatment group\\r\\nAdminister GRA 1mg intraven...                  [肺がん]  \n",
+       "...                                                 ...                    ...  \n",
+       "974   Experimental: Arm 1A: T-DXd and 5-fluorouracil...  [胃腺癌, 胃食道接合部腺癌, 食道腺癌]  \n",
+       "981   Inject the investigational drug (Cellm-001 or ...                  [膠芽腫]  \n",
+       "996   S-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da...               [4型進行胃癌]  \n",
+       "1053  Test drug (T-hIL12) will be administered into ...                [悪性黒色腫]  \n",
+       "1067  combination therapy of intracutaneous GEN0101 ...             [進行性悪性黒色腫]  \n",
+       "\n",
+       "[416 rows x 39 columns]"
+      ]
+     },
+     "execution_count": 84,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "basedf"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 89,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stderr",
+     "output_type": "stream",
+     "text": [
+      "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
+      "  warnings.warn(\n"
+     ]
+    }
+   ],
+   "source": [
+    "# クエリ\n",
+    "query = \"乳がん\"\n",
+    "\n",
+    "# モデルのロード\n",
+    "model = SentenceTransformer('all-MiniLM-L6-v2')\n",
+    "\n",
+    "# クエリをベクトル化\n",
+    "query_vec = model.encode(query, convert_to_tensor=True)\n"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 102,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# ターゲットリスト全体を処理\n",
+    "matched_indices = []\n",
+    "target_vecs_list = []\n",
+    "cosine_scores_list = []\n",
+    "for idx, target_words in enumerate(basedf['TargetWord']):\n",
+    "    # ターゲット内の各単語をベクトル化\n",
+    "    target_vecs = model.encode(target_words, convert_to_tensor=True)\n",
+    "    # コサイン類似度を計算\n",
+    "    cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n",
+    "    target_vecs_list.append(target_vecs)\n",
+    "    cosine_scores_list.append(cosine_scores)\n",
+    "    # 閾値を超えるか確認\n",
+    "    if (cosine_scores >= 0.7).any():  # いずれかが閾値を超えている場合\n",
+    "        matched_indices.append(idx)\n",
+    "\n",
+    "# 抽出\n",
+    "matched_df = basedf.iloc[matched_indices]"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 113,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/plain": [
+       "4"
+      ]
+     },
+     "execution_count": 113,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "matched_indices[0]"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 115,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stdout",
+     "output_type": "stream",
+     "text": [
+      "tensor(1., device='mps:0')\n",
+      "tensor([0.5316, 0.7820, 0.9005, 0.6651, 0.6537], device='mps:0')\n",
+      "tensor(0.7820, device='mps:0')\n",
+      "tensor([0.8813, 0.7659, 0.7375, 0.6654], device='mps:0')\n",
+      "tensor([0.4314, 0.7559], device='mps:0')\n",
+      "tensor(0.7012, device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor([0.8813, 0.6887, 0.7659], device='mps:0')\n",
+      "tensor(0.7820, device='mps:0')\n",
+      "tensor(0.7820, device='mps:0')\n",
+      "tensor(0.7190, device='mps:0')\n",
+      "tensor(1., device='mps:0')\n",
+      "tensor([0.8813, 0.6887, 0.7659], device='mps:0')\n",
+      "tensor([0.5691, 0.9683], device='mps:0')\n",
+      "tensor([1.0000, 0.5633, 0.8272], device='mps:0')\n",
+      "tensor(0.7820, device='mps:0')\n",
+      "tensor([0.4257, 0.7559], device='mps:0')\n",
+      "tensor([0.6060, 0.8272], device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor([0.4901, 0.7075], device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor([1.0000, 0.9335], device='mps:0')\n",
+      "tensor(0.7103, device='mps:0')\n",
+      "tensor([0.6060, 0.9335], device='mps:0')\n",
+      "tensor([0.6060, 0.8272, 0.6060, 0.5189, 0.6060, 0.5161], device='mps:0')\n",
+      "tensor([0.7628, 0.4268, 0.1960], device='mps:0')\n",
+      "tensor([0.9683, 0.5335], device='mps:0')\n",
+      "tensor(0.7223, device='mps:0')\n",
+      "tensor([0.5981, 0.4374, 0.4223, 0.5691, 0.9683], device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor([0.5651, 0.8813], device='mps:0')\n",
+      "tensor([0.9683, 0.4708, 0.5691], device='mps:0')\n",
+      "tensor([0.5039, 0.4994, 0.9005, 0.9683], device='mps:0')\n",
+      "tensor([1.0000, 0.9335], device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor(0.7659, device='mps:0')\n",
+      "tensor([0.5464, 0.8813], device='mps:0')\n",
+      "tensor([0.5633, 1.0000], device='mps:0')\n",
+      "tensor(0.9387, device='mps:0')\n",
+      "tensor([0.6637, 0.5138, 0.9683, 0.4046, 0.4765], device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor(1., device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor([0.6060, 0.8272], device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n",
+      "tensor([0.5651, 0.8813], device='mps:0')\n",
+      "tensor(1., device='mps:0')\n",
+      "tensor([0.7099, 0.7024], device='mps:0')\n",
+      "tensor(0.7820, device='mps:0')\n",
+      "tensor(0.8280, device='mps:0')\n",
+      "tensor([0.9683, 0.8464, 0.0214, 0.1548], device='mps:0')\n",
+      "tensor(0.9683, device='mps:0')\n"
+     ]
+    }
+   ],
+   "source": [
+    "for n in matched_indices:\n",
+    "    print(cosine_scores_list[n])"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 106,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stdout",
+     "output_type": "stream",
+     "text": [
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([3, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([5, 384])\n",
+      "torch.Size([3, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([4, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([4, 384])\n",
+      "torch.Size([3, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([3, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([4, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([4, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([5, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([3, 384])\n",
+      "torch.Size([4, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([3, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([3, 384])\n",
+      "torch.Size([3, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([2, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([1, 384])\n",
+      "torch.Size([3, 384])\n"
+     ]
+    }
+   ],
+   "source": [
+    "for i in range(100):\n",
+    "    print(target_vecs_list[i].shape)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 108,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stdout",
+     "output_type": "stream",
+     "text": [
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([3])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([5])\n",
+      "torch.Size([3])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([2])\n",
+      "torch.Size([4])\n",
+      "torch.Size([])\n",
+      "torch.Size([4])\n",
+      "torch.Size([3])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([3])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([4])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([4])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([5])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([3])\n",
+      "torch.Size([4])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([3])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([3])\n",
+      "torch.Size([3])\n",
+      "torch.Size([])\n",
+      "torch.Size([2])\n",
+      "torch.Size([])\n",
+      "torch.Size([])\n",
+      "torch.Size([3])\n"
+     ]
+    }
+   ],
+   "source": [
+    "for i in range(100):\n",
+    "    print(cosine_scores_list[i].shape)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 111,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/plain": [
+       "tensor(0.5400, device='mps:0')"
+      ]
+     },
+     "execution_count": 111,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "cosine_scores_list[0]"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 85,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stderr",
+     "output_type": "stream",
+     "text": [
+      "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
+      "  warnings.warn(\n"
+     ]
+    }
+   ],
+   "source": [
+    "# 日本語対応マルチリンガルモデルを使用(例: 'distiluse-base-multilingual-cased-v1')\n",
+    "model_name = 'sentence-transformers/distiluse-base-multilingual-cased-v1'\n",
+    "model = SentenceTransformer(model_name)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 50,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# クエリ例\n",
+    "query = \"神経膠腫\"\n",
+    "# クエリのベクトル化\n",
+    "query_vec = model.encode(query, convert_to_tensor=True)\n",
+    "\n",
+    "# 全データのターゲット列をベクトル化\n",
+    "target_list = basedf['Target'].tolist()\n",
+    "target_vecs = model.encode(target_list, convert_to_tensor=True)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 51,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# コサイン類似度を計算\n",
+    "cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 56,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "threshold = 0.7\n",
+    "# nonzero()の返り値はタプル (indices_array, ) なので [0] でインデックス配列を取得\n",
+    "matched_indices = (cosine_scores >= threshold).nonzero().tolist()\n",
+    "# 入れ子リストをフラットなリストに変換\n",
+    "flat_indices = [idx[0] for idx in matched_indices]\n",
+    "\n",
+    "# 抽出\n",
+    "matched_df = basedf.iloc[flat_indices]\n"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": []
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 57,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>JRCT ID</th>\n",
+       "      <th>NCT No</th>\n",
+       "      <th>JapicCTI No</th>\n",
+       "      <th>Title</th>\n",
+       "      <th>Target</th>\n",
+       "      <th>研究・治験の目的</th>\n",
+       "      <th>試験等のフェーズ</th>\n",
+       "      <th>試験の種類</th>\n",
+       "      <th>無作為化</th>\n",
+       "      <th>盲検化</th>\n",
+       "      <th>...</th>\n",
+       "      <th>assignment</th>\n",
+       "      <th>purpose</th>\n",
+       "      <th>Inclusion Criteria</th>\n",
+       "      <th>Exclusion Criteria</th>\n",
+       "      <th>Age Minimum</th>\n",
+       "      <th>Age Maximum</th>\n",
+       "      <th>Gender</th>\n",
+       "      <th>Discontinuation Criteria</th>\n",
+       "      <th>Keyword</th>\n",
+       "      <th>Intervention(s)</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>67</th>\n",
+       "      <td>jRCT2051240150</td>\n",
+       "      <td>NCT06622941</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>ONO-4538-126：ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検...</td>\n",
+       "      <td>ラブドイド腫瘍</td>\n",
+       "      <td>ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検討する</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>single assignment</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Gender: Not specified\\r\\n2. Age (at the tim...</td>\n",
+       "      <td>1. Patients with a history of active concurren...</td>\n",
+       "      <td>1age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>For adults, Nivolumab (recombinant) is adminis...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>103</th>\n",
+       "      <td>jRCT2051240121</td>\n",
+       "      <td>NCT06413706</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...</td>\n",
+       "      <td>悪性神経膠腫</td>\n",
+       "      <td>放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>parallel assignment</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Subjects required to meet all the folloiwng cr...</td>\n",
+       "      <td>Patients who meets any of the following criter...</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>21age old not</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>224</th>\n",
+       "      <td>jRCT2031240090</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...</td>\n",
+       "      <td>悪性神経膠腫</td>\n",
+       "      <td>再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>parallel assignment</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1) Histologically diagnosed as high grade glio...</td>\n",
+       "      <td>1) Have a history or merger of other malignanc...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>75age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>glioblastoma, grade3/4 astrocytoma, grade3 oli...</td>\n",
+       "      <td>Group A: BPC Therapy\\r\\nDepending on the patie...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>286</th>\n",
+       "      <td>jRCT2071230124</td>\n",
+       "      <td>NCT06541665</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40...</td>\n",
+       "      <td>中枢神経系原発リンパ腫</td>\n",
+       "      <td>未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>single assignment</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Patients diagnosed with PCNSL\\r\\n2. Patient...</td>\n",
+       "      <td>1.Patients with intraocular PCNSL without brai...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Concomitant administration of ONO-4059 and rit...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>321</th>\n",
+       "      <td>jRCT2071230114</td>\n",
+       "      <td>NCT06240741</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを...</td>\n",
+       "      <td>神経内分泌腫瘍（NEN）</td>\n",
+       "      <td>神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>single assignment</td>\n",
+       "      <td>diagnostic purpose</td>\n",
+       "      <td>1. Signed informed consent must be obtained pr...</td>\n",
+       "      <td>1. Inability to complete the needed investigat...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>[68Ga]Ga-DOTA-TATE will be administered intrav...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>338</th>\n",
+       "      <td>jRCT2041230136</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験</td>\n",
+       "      <td>再発膠芽腫</td>\n",
+       "      <td>再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>single assignment</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(1) Patients with a histological diagnosis of ...</td>\n",
+       "      <td>(1) Patients with extracerebral metastases.\\r\\...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>75age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Dosing frequency: 1 time /week\\r\\nDose Levels\\...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>349</th>\n",
+       "      <td>jRCT2032230554</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>初発膠芽腫に対する新型高出力中性子線源を用いた加速器BNCT装置iBNCT001及びSPM-...</td>\n",
+       "      <td>初発膠芽腫</td>\n",
+       "      <td>治験機器iBNCT001及び治験薬SPM-011を用いたホウ素中性子捕捉療法（BNCT）に、...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>非無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>single assignment</td>\n",
+       "      <td>other</td>\n",
+       "      <td>- Karnofsky Performance Status is greater than...</td>\n",
+       "      <td>- Multiple lesions, bilateral lesions, dissemi...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>85age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>boron, neutron, glioblastoma</td>\n",
+       "      <td>- Intravenous administration of investigationa...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>473</th>\n",
+       "      <td>jRCT2051230069</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
+       "      <td>神経膠腫</td>\n",
+       "      <td>神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>single assignment</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>&lt;Cohort 1&gt;\\r\\n All of the following items shal...</td>\n",
+       "      <td>&lt;Common to Cohort 1 and Cohort 2&gt;\\r\\n1) Active...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>&lt;cohort1&gt;\\r\\nLomustine 130 mg/m2 orally every ...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>476</th>\n",
+       "      <td>jRCT2021230016</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>皮膚血管肉腫に対するパクリタキセルとTM5614併用の安全性・有効性を検討する第Ⅱ相医師主導治験</td>\n",
+       "      <td>皮膚血管肉腫</td>\n",
+       "      <td>皮膚血管肉腫のパクリタキセル単剤療法無効症例を対象にTM5614とパクリタキセルの併用時にお...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>single assignment</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(1) Patients who are 18 years old over (at the...</td>\n",
+       "      <td>(1) Patients with concomitant or pre-existing ...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>(TM5614)\\r\\nTM5614 should be taken orally afte...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>875</th>\n",
+       "      <td>jRCT2031210299</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験</td>\n",
+       "      <td>再発悪性神経膠腫</td>\n",
+       "      <td>再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>single assignment</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1.\\tEstimated life expectancy &gt;= 3 months\\r\\n2...</td>\n",
+       "      <td>1.\\tPrior therapy with bevacizumab or other an...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Patients will receive DSP-0390 orally once dai...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>981</th>\n",
+       "      <td>jRCT2031200153</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Cellm-001による初発膠芽腫治療効果無作為比較対照試験</td>\n",
+       "      <td>膠芽腫</td>\n",
+       "      <td>脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>二重盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>parallel assignment</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(1) 18 years old or older and 75 years old or ...</td>\n",
+       "      <td>(1) Systemic administration of corticosteroids...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>75age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Inject the investigational drug (Cellm-001 or ...</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>11 rows × 38 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "            JRCT ID       NCT No JapicCTI No  \\\n",
+       "67   jRCT2051240150  NCT06622941         NaN   \n",
+       "103  jRCT2051240121  NCT06413706         NaN   \n",
+       "224  jRCT2031240090          NaN         NaN   \n",
+       "286  jRCT2071230124  NCT06541665         NaN   \n",
+       "321  jRCT2071230114  NCT06240741         NaN   \n",
+       "338  jRCT2041230136          NaN         NaN   \n",
+       "349  jRCT2032230554          NaN         NaN   \n",
+       "473  jRCT2051230069          NaN         NaN   \n",
+       "476  jRCT2021230016          NaN         NaN   \n",
+       "875  jRCT2031210299          NaN         NaN   \n",
+       "981  jRCT2031200153          NaN         NaN   \n",
+       "\n",
+       "                                                 Title        Target  \\\n",
+       "67   ONO-4538-126：ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検...       ラブドイド腫瘍   \n",
+       "103  放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...        悪性神経膠腫   \n",
+       "224  再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...        悪性神経膠腫   \n",
+       "286  ONO-4059-13:未治療の中枢神経系原発リンパ腫（PCNSL）を対象としたONO-40...   中枢神経系原発リンパ腫   \n",
+       "321  日本の神経内分泌腫瘍（NEN）患者及び健康成人を対象に[68Ga]Ga-DOTA-TATEを...  神経内分泌腫瘍（NEN）   \n",
+       "338                   再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験         再発膠芽腫   \n",
+       "349  初発膠芽腫に対する新型高出力中性子線源を用いた加速器BNCT装置iBNCT001及びSPM-...         初発膠芽腫   \n",
+       "473  神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...          神経膠腫   \n",
+       "476   皮膚血管肉腫に対するパクリタキセルとTM5614併用の安全性・有効性を検討する第Ⅱ相医師主導治験        皮膚血管肉腫   \n",
+       "875                     再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験      再発悪性神経膠腫   \n",
+       "981                     Cellm-001による初発膠芽腫治療効果無作為比較対照試験           膠芽腫   \n",
+       "\n",
+       "                                              研究・治験の目的 試験等のフェーズ 試験の種類  \\\n",
+       "67                ラブドイド腫瘍を対象としたONO-4538 の有効性及び安全性を検討する        2   NaN   \n",
+       "103  放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...        2   NaN   \n",
+       "224  再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...        3   NaN   \n",
+       "286  未治療PCNSL患者を対象にONO-4059 とR-MPV 療法を併用投与したときの忍容性及...        1   NaN   \n",
+       "321  神経内分泌腫瘍（NEN）患者及び健康成人（HV）を対象に，[68Ga]Ga-DOTA-TAT...        3   NaN   \n",
+       "338  再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を...        1   NaN   \n",
+       "349  治験機器iBNCT001及び治験薬SPM-011を用いたホウ素中性子捕捉療法（BNCT）に、...        1   NaN   \n",
+       "473  神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...        1   NaN   \n",
+       "476  皮膚血管肉腫のパクリタキセル単剤療法無効症例を対象にTM5614とパクリタキセルの併用時にお...        2   NaN   \n",
+       "875  再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...        1   NaN   \n",
+       "981  脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...        3   NaN   \n",
+       "\n",
+       "        無作為化   盲検化  ...           assignment             purpose  \\\n",
+       "67       単一群   非盲検  ...    single assignment   treatment purpose   \n",
+       "103   無作為化比較   非盲検  ...  parallel assignment   treatment purpose   \n",
+       "224   無作為化比較   非盲検  ...  parallel assignment   treatment purpose   \n",
+       "286      単一群   非盲検  ...    single assignment   treatment purpose   \n",
+       "321      単一群   非盲検  ...    single assignment  diagnostic purpose   \n",
+       "338      単一群   非盲検  ...    single assignment   treatment purpose   \n",
+       "349  非無作為化比較   非盲検  ...    single assignment               other   \n",
+       "473      単一群   非盲検  ...    single assignment   treatment purpose   \n",
+       "476      単一群   非盲検  ...    single assignment   treatment purpose   \n",
+       "875      単一群   非盲検  ...    single assignment   treatment purpose   \n",
+       "981   無作為化比較  二重盲検  ...  parallel assignment   treatment purpose   \n",
+       "\n",
+       "                                    Inclusion Criteria  \\\n",
+       "67   1. Gender: Not specified\\r\\n2. Age (at the tim...   \n",
+       "103  Subjects required to meet all the folloiwng cr...   \n",
+       "224  1) Histologically diagnosed as high grade glio...   \n",
+       "286  1. Patients diagnosed with PCNSL\\r\\n2. Patient...   \n",
+       "321  1. Signed informed consent must be obtained pr...   \n",
+       "338  (1) Patients with a histological diagnosis of ...   \n",
+       "349  - Karnofsky Performance Status is greater than...   \n",
+       "473  <Cohort 1>\\r\\n All of the following items shal...   \n",
+       "476  (1) Patients who are 18 years old over (at the...   \n",
+       "875  1.\\tEstimated life expectancy >= 3 months\\r\\n2...   \n",
+       "981  (1) 18 years old or older and 75 years old or ...   \n",
+       "\n",
+       "                                    Exclusion Criteria     Age Minimum  \\\n",
+       "67   1. Patients with a history of active concurren...   1age old over   \n",
+       "103  Patients who meets any of the following criter...        No limit   \n",
+       "224  1) Have a history or merger of other malignanc...  18age old over   \n",
+       "286  1.Patients with intraocular PCNSL without brai...  18age old over   \n",
+       "321  1. Inability to complete the needed investigat...  18age old over   \n",
+       "338  (1) Patients with extracerebral metastases.\\r\\...  18age old over   \n",
+       "349  - Multiple lesions, bilateral lesions, dissemi...  18age old over   \n",
+       "473  <Common to Cohort 1 and Cohort 2>\\r\\n1) Active...  18age old over   \n",
+       "476  (1) Patients with concomitant or pre-existing ...  18age old over   \n",
+       "875  1.\\tPrior therapy with bevacizumab or other an...  18age old over   \n",
+       "981  (1) Systemic administration of corticosteroids...  18age old over   \n",
+       "\n",
+       "         Age Maximum Gender Discontinuation Criteria  \\\n",
+       "67          No limit   Both                      NaN   \n",
+       "103    21age old not    NaN                      NaN   \n",
+       "224  75age old under   Both                      NaN   \n",
+       "286         No limit   Both                      NaN   \n",
+       "321         No limit   Both                      NaN   \n",
+       "338  75age old under   Both                      NaN   \n",
+       "349  85age old under   Both                      NaN   \n",
+       "473         No limit   Both                      NaN   \n",
+       "476         No limit   Both                      NaN   \n",
+       "875         No limit   Both                      NaN   \n",
+       "981  75age old under   Both                      NaN   \n",
+       "\n",
+       "                                               Keyword  \\\n",
+       "67                                                 NaN   \n",
+       "103                                                NaN   \n",
+       "224  glioblastoma, grade3/4 astrocytoma, grade3 oli...   \n",
+       "286                                                NaN   \n",
+       "321                                                NaN   \n",
+       "338                                                NaN   \n",
+       "349                       boron, neutron, glioblastoma   \n",
+       "473                                                NaN   \n",
+       "476                                                NaN   \n",
+       "875                                                NaN   \n",
+       "981                                                NaN   \n",
+       "\n",
+       "                                       Intervention(s)  \n",
+       "67   For adults, Nivolumab (recombinant) is adminis...  \n",
+       "103  Drug: Abemaciclib\\r\\nAdministered orally\\r\\nOt...  \n",
+       "224  Group A: BPC Therapy\\r\\nDepending on the patie...  \n",
+       "286  Concomitant administration of ONO-4059 and rit...  \n",
+       "321  [68Ga]Ga-DOTA-TATE will be administered intrav...  \n",
+       "338  Dosing frequency: 1 time /week\\r\\nDose Levels\\...  \n",
+       "349  - Intravenous administration of investigationa...  \n",
+       "473  <cohort1>\\r\\nLomustine 130 mg/m2 orally every ...  \n",
+       "476  (TM5614)\\r\\nTM5614 should be taken orally afte...  \n",
+       "875  Patients will receive DSP-0390 orally once dai...  \n",
+       "981  Inject the investigational drug (Cellm-001 or ...  \n",
+       "\n",
+       "[11 rows x 38 columns]"
+      ]
+     },
+     "execution_count": 57,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "matched_df"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 58,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/plain": [
+       "['尿路上皮癌',\n",
+       " '切除不能進行・再発胃癌',\n",
+       " '非小細胞肺癌',\n",
+       " '進行性悪性固形癌\\n転移性悪性固形癌',\n",
+       " '肺がん',\n",
+       " '胃腺癌及び食道胃接合部腺癌',\n",
+       " '非扁平上皮非小細胞肺癌',\n",
+       " '未治療の濾胞性リンパ腫',\n",
+       " 'ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する固形がん',\n",
+       " 'MET過剰発現を有する非小細胞肺癌',\n",
+       " '進行／転移性固形癌',\n",
+       " '頭頸部扁平上皮癌',\n",
+       " '転移性膵管腺癌（mPDAC）',\n",
+       " '前立腺癌',\n",
+       " 'トリプルネガティブ乳癌',\n",
+       " 'HR+/HER2-の切除不能局所進行又は転移性乳癌の患者',\n",
+       " '未治療の転移性非扁平上皮非小細胞肺癌（NSCLC）',\n",
+       " 'PD-L1陽性の転移性非小細胞肺癌',\n",
+       " '去勢抵抗性前立腺癌',\n",
+       " '切除不能皮膚血管肉腫',\n",
+       " 'PD-L1陽性の未治療の転移性非小細胞肺癌',\n",
+       " 'NSQ, NSCLC',\n",
+       " '卵巣癌、腹膜癌及び卵管癌',\n",
+       " '進行固形癌',\n",
+       " '進行固形癌',\n",
+       " '進展型小細胞肺癌',\n",
+       " '高リスク大細胞型B細胞リンパ腫',\n",
+       " '子宮体癌',\n",
+       " 'HER2陽性転移性乳癌',\n",
+       " '・進行性固形腫瘍・進行性乳がん・転移性乳がん・ホルモン受容体陽性乳がん・ホルモン受容体陽性乳がん...',\n",
+       " '膵管腺癌\\n非小細胞肺癌\\n大腸癌',\n",
+       " '進行固形がん',\n",
+       " '非小細胞肺癌',\n",
+       " 'ラブドイド腫瘍',\n",
+       " '非小細胞肺癌',\n",
+       " '膵癌',\n",
+       " '非ホジキンリンパ腫',\n",
+       " 'H3 K27M 変異を有する初発びまん性神経膠腫',\n",
+       " '胃癌、胃食道接合部癌',\n",
+       " '局所進行又は再発性の外陰癌・腟癌・子宮頸癌',\n",
+       " '固形癌',\n",
+       " '転移性固形がん\\n進行性固形がん\\n非小細胞肺がん\\nSMARCA4欠損がん',\n",
+       " '卵巣癌\\n子宮内膜癌\\n非小細胞肺癌',\n",
+       " '再発・難治性多発性骨髄腫',\n",
+       " '転移性去勢抵抗性前立腺癌',\n",
+       " 'Up-to-7基準外の中期肝細胞癌',\n",
+       " '進行性非小細胞肺癌（NSCLC）及びその他の固形がん',\n",
+       " '転移性肝臓癌',\n",
+       " '悪性神経膠腫',\n",
+       " '転移性非小細胞肺がん',\n",
+       " '固形がん',\n",
+       " '再発多形性膠芽腫',\n",
+       " '転移性膵管腺癌',\n",
+       " '転移性固形がん\\n再発性固形がん\\n進行性固形がん',\n",
+       " '非小細胞肺癌',\n",
+       " '再発性低悪性度漿液性卵巣癌（LGSOC）',\n",
+       " 'B細胞性非ホジキンリンパ腫\\n- 濾胞性リンパ腫(FL)\\n- びまん性大細胞型B細胞リンパ腫(DLBCL)',\n",
+       " '非小細胞肺癌',\n",
+       " '遠隔転移を伴う結腸・直腸癌',\n",
+       " '進行固形がん',\n",
+       " '肝細胞癌',\n",
+       " '進行又は転移例に対する標準治療による治療歴のあるKRAS G12C陽性進行又は転移性非小細胞肺癌',\n",
+       " '●固形腫瘍',\n",
+       " '進行固形がん',\n",
+       " '非小細胞性肺がん',\n",
+       " '進行性固形癌',\n",
+       " 'B細胞性非ホジキンリンパ腫 (NHL) \\n慢性リンパ性白血病 (CLL)',\n",
+       " '進行非小細胞肺がん',\n",
+       " 'びまん性大細胞型 B 細胞リンパ腫',\n",
+       " '進行固形癌',\n",
+       " '非小細胞肺癌',\n",
+       " 'HER2遺伝子異常を伴う固形腫瘍',\n",
+       " '固形腫瘍',\n",
+       " '子宮頸癌\\n胃/胃食道接合部腺癌\\nマイクロサテライト安定性結腸直腸癌\\n非小細胞肺癌\\n頭頸部扁平上皮癌...',\n",
+       " '胆道癌',\n",
+       " '転移性去勢抵抗性前立腺癌',\n",
+       " 'HER2陽性の進行性又は転移性の胆道癌',\n",
+       " '進行期乳房外パジェット病',\n",
+       " '多発性骨髄腫',\n",
+       " '転移性去勢抵抗性前立腺癌',\n",
+       " '非小細胞肺癌',\n",
+       " '濾胞性リンパ腫',\n",
+       " '非小細胞肺癌',\n",
+       " '未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫',\n",
+       " '標準治療がない、または標準治療に不応もしくは不耐の根治切除不能な進行・再発固形がん患者',\n",
+       " '扁平上皮非小細胞肺癌',\n",
+       " '子宮頸癌',\n",
+       " '非小細胞肺癌',\n",
+       " '大細胞型B細胞リンパ腫',\n",
+       " '非ホジキンリンパ腫\\n難治性B細胞性非ホジキンリンパ腫\\n再発B細胞性非ホジキンリンパ��',\n",
+       " '多発性骨髄腫、慢性骨髄性白血病',\n",
+       " 'HER2発現を有する固形癌',\n",
+       " '限局型小細胞肺癌',\n",
+       " '結腸直腸癌、膵管腺癌、胆道癌',\n",
+       " '\"再発又は難治性の多発性骨髄腫\\n治療歴のあるアミロイド軽鎖（AL）アミロイドーシス\"',\n",
+       " '固形癌',\n",
+       " '進行性又は転移性非扁平上皮非小細胞肺癌',\n",
+       " '未治療のFLIPI 2～5の濾胞性リンパ腫患者',\n",
+       " '再発進行原発性肺腺癌',\n",
+       " '臨床病期II期またはIII期と診断され、かつ切除可能な乳癌',\n",
+       " '臨床病期II期またはIII期と診断され、かつ切除可能な乳癌',\n",
+       " '乳がん',\n",
+       " '食道癌（扁平上皮癌）',\n",
+       " '多発性骨髄腫',\n",
+       " '非小細胞肺癌',\n",
+       " '胃腺癌、食道胃接合部腺癌及び食道腺癌',\n",
+       " '転移性乳癌（mBC）及び進行または転移性胃又は胃食道接合部又は食道腺癌（mGEAC）患者',\n",
+       " '進展型小細胞肺癌\\n小細胞肺癌',\n",
+       " '非小細胞肺癌',\n",
+       " '進行固形癌',\n",
+       " '筋層非浸潤性膀胱癌',\n",
+       " '非小細胞肺癌',\n",
+       " '去勢抵抗性前立腺癌',\n",
+       " '進行乳癌',\n",
+       " '進展型小細胞肺癌',\n",
+       " '悪性神経膠腫',\n",
+       " '転移性固形がん\\n再発性固形がん\\n進行性固形がん',\n",
+       " '成人T細胞白血病・リンパ腫',\n",
+       " '子宮体がん',\n",
+       " '非小細胞肺癌',\n",
+       " '進行小細胞肺癌',\n",
+       " '卵巣癌・固形がん',\n",
+       " '転移性結腸直腸癌',\n",
+       " '未治療の転移性非扁平上皮非小細胞肺癌（NSCLC）',\n",
+       " '筋層非浸潤性膀胱癌',\n",
+       " '子宮体癌',\n",
+       " '転移性前立腺癌',\n",
+       " '転移性前立腺癌',\n",
+       " '再発又は難治性の多発性骨髄腫',\n",
+       " '肺がん、食道がん、胃癌等の固形がん',\n",
+       " '子宮内膜癌、頭頸部扁平上皮癌、膵管腺癌、大腸癌、肝細胞癌、食道腺癌／食道胃接合部腺癌／胃腺癌、尿...',\n",
+       " '多発性骨髄腫',\n",
+       " '成人T細胞白血病リンパ腫',\n",
+       " '再発又は難治性の多発性骨髄腫',\n",
+       " 'HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌',\n",
+       " '進行固形がん',\n",
+       " '子宮体癌',\n",
+       " '悪性胸膜中皮腫',\n",
+       " '乳癌',\n",
+       " '非小細胞肺癌',\n",
+       " '進行固形癌',\n",
+       " '固形癌',\n",
+       " '中枢神経系原発リンパ腫',\n",
+       " '慢性リンパ性白血病／小リンパ球性リンパ腫',\n",
+       " '悪性黒色腫',\n",
+       " '再発小細胞肺癌',\n",
+       " '進行NSCLC 及びその他の固形がん',\n",
+       " 'ホルモン受容体（HR）陽性ヒト上皮増殖因子受容体2（HER2）陰性の進行または転移乳癌',\n",
+       " '扁平上皮非小細胞肺がん',\n",
+       " '転移性非扁平上皮非小細胞肺癌',\n",
+       " '固形腫瘍及び血液学的悪性腫瘍',\n",
+       " '非小細胞肺癌',\n",
+       " '進行性又は転移性の固形がん',\n",
+       " 'エストロゲン受容体陽性／ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌',\n",
+       " '未治療の大細胞型B細胞リンパ腫患者',\n",
+       " '多発性骨髄腫',\n",
+       " '乳癌',\n",
+       " '固形がん',\n",
+       " '局所進行（切除不能）及び／又は遠隔転移を伴うHER2発現癌',\n",
+       " '多発性骨髄腫',\n",
+       " '再発小細胞肺癌（SCLC）',\n",
+       " '神経内分泌腫瘍（NEN）',\n",
+       " '固形癌',\n",
+       " '組織学的又は細胞学的に確認されたES-SCLC',\n",
+       " '再発又は難治性濾胞性リンパ腫',\n",
+       " 'CIでM1のないPSMA-PETによるオリゴ転移性前立腺がん（OMPC）',\n",
+       " '再発・難治性のマントル細胞リンパ腫又は再発・難治性の前駆B細胞性急性リンパ芽球性白血病',\n",
+       " '再発または難治性多発性骨髄腫',\n",
+       " '多発性骨髄腫',\n",
+       " '限局型小細胞肺癌\\n小細胞肺癌',\n",
+       " '本治験の被験者は，アジアの実施医療機関から参加する，確立された治療が無効である又はその適応ではな...',\n",
+       " '再発膠芽腫',\n",
+       " '局所進行又は転移性固形癌',\n",
+       " '局所進行頭頸部扁平上皮癌',\n",
+       " 'MTAP 欠損固形がん患者',\n",
+       " '古典的ホジキンリンパ腫及び非ホジキンリンパ腫',\n",
+       " '胃癌、食道胃接合部癌、膵管腺癌',\n",
+       " '転移性去勢感受性前立腺癌',\n",
+       " '局所進行頭頸���扁平上皮癌',\n",
+       " '初発膠芽腫',\n",
+       " '肝細胞癌，膵管腺癌，胆道癌，食道扁平上皮癌，乳癌，頭頚部扁平上皮癌',\n",
+       " '固形がん',\n",
+       " '多発性骨髄腫',\n",
+       " '手術不能かつ既存治療不応の進行・再発固形がん',\n",
+       " '早期又は進行／転移性の固形がん',\n",
+       " '非小細胞肺癌',\n",
+       " '非小細胞肺癌\\n転移性腫瘍',\n",
+       " '固形癌',\n",
+       " '新生物',\n",
+       " '胆道癌',\n",
+       " '潜在的にSEZ6を発現する進行固形がん',\n",
+       " '肺外神経内分泌癌（ただしメルケル細胞癌，甲状腺髄様癌又はグレード3の神経内分泌腫瘍を除く）\\n肺の大...',\n",
+       " '非小細胞肺癌（NSCLC）',\n",
+       " 'HER2 TKD変異を有する切除不能，局所進行又は転移性非扁平上皮非小細胞肺癌',\n",
+       " '再発又は難治性の多発性骨髄腫（RRMM）',\n",
+       " '多発性骨髄腫',\n",
+       " 'HER2低発現の胃腺癌又は胃食道接合部腺癌又は食道腺癌',\n",
+       " '未治療多発性骨髄腫',\n",
+       " '再発又は難治性のT細胞リンパ腫及び慢性リンパ性白血病/小リンパ球性リンパ腫',\n",
+       " '消化器（消化管・肝胆膵）神経内分泌癌',\n",
+       " '直腸がん',\n",
+       " '切除不能な胸膜中皮腫',\n",
+       " '乳がん、早期乳がん',\n",
+       " '切除不能な転移性結腸・直腸癌',\n",
+       " '悪性固形腫瘍',\n",
+       " '局所進行子宮頸癌',\n",
+       " '遠隔転移を有する膵がん',\n",
+       " '• パート1: 局所進行又は転移性固形癌\\n• パート2: 胃腺癌、食道胃接合部腺癌、食道腺癌又は非小細胞肺癌',\n",
+       " '非小細胞肺癌',\n",
+       " '進行性又は転移性がん',\n",
+       " '再発及び難治性の多発性骨髄腫',\n",
+       " '大細胞型B細胞性リンパ腫、濾胞性リンパ腫',\n",
+       " '進行性又は転移性の固形がん、進行性又は転移性の食道癌、進行性又は転移性の頭頸部扁平上皮癌',\n",
+       " '再発又は遠隔転移を有する頭頸部癌',\n",
+       " '再発又は難治性のT細胞リンパ腫',\n",
+       " '急性白血病（慢性白血病の急性転化例を含む）、悪性リンパ腫\\nただし、L-アスパラギナーゼ製剤に過敏症...',\n",
+       " '黒色腫',\n",
+       " '固形がん（Arm 1）、非小細胞肺癌（Arm 2及びArm 3）',\n",
+       " 'EGFRのエクソン20挿入変異を有する局所進行又は転移性非扁平上皮非小細胞肺癌',\n",
+       " 'EGFRのエクソン20挿入変異及びUncommon/Single又はCompound変異を有する局所進行又は転移性非小細胞肺癌',\n",
+       " '用量漸増部分：組織型を問わず，KRAS wt増幅又はKRAS G12V変異を有する治療選択肢が限られている固形癌...',\n",
+       " 'B細胞性非ホジキンリンパ腫',\n",
+       " '再発若しくは転移性又は切除不能な局所進行の有棘細胞癌',\n",
+       " '胃腺がん, 胃食道接合部(GEJ)腺がん',\n",
+       " '前立腺癌',\n",
+       " '臨床的に遠隔転移のない膵がん',\n",
+       " '癌関連静脈血栓塞栓症',\n",
+       " '尿路上皮癌',\n",
+       " 'CRPCコホート\\n転移性去勢抵抗性前立腺癌',\n",
+       " '標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん',\n",
+       " 'KRAS wt増幅を有する固形癌（GAC，EAC，及びGEJAC）\\n組織型を問わず，KRAS wt増幅又はKRAS G12V変異を...',\n",
+       " '癌',\n",
+       " '中枢神経系原発悪性リンパ腫',\n",
+       " '肝細胞癌、胆道癌',\n",
+       " 'エストロゲン受容体陽性／ヒト上皮増殖因子受容体2陰性の進行乳癌',\n",
+       " '血液がん',\n",
+       " '筋層浸潤性膀胱癌',\n",
+       " 'びまん性大細胞型B細胞リンパ腫 ',\n",
+       " '非小細胞肺癌',\n",
+       " '神経膠腫',\n",
+       " '局所進行、転移性、又は切除不能な固形癌',\n",
+       " '皮膚血管肉腫',\n",
+       " '局所進行又は転移性固形がん',\n",
+       " '胆道癌',\n",
+       " '固形癌',\n",
+       " '多発性骨髄腫',\n",
+       " '多発性骨髄腫',\n",
+       " '結腸癌',\n",
+       " '胃癌\\n食道胃接合部癌\\n膵臓線癌\\n食道線癌',\n",
+       " '進行切除不能肝細胞癌',\n",
+       " '頭頸部癌',\n",
+       " '卵巣癌',\n",
+       " '胃腺癌、胃食道接合部（GEJ）腺癌、及び食道腺癌を含む進行性又は転移性GEA患者',\n",
+       " '筋層非浸潤性膀胱癌',\n",
+       " '未治療の切除不能または再発胸腺癌',\n",
+       " '乳癌',\n",
+       " '局所進行又は転移性非扁平上皮非小細胞肺癌',\n",
+       " '膀胱がん\\n���移性腫瘍\\n尿管癌',\n",
+       " '再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん',\n",
+       " '乳がん、早期乳がん',\n",
+       " '進行性の切除不能又は転移性MSIhi 又はdMMR固形がん，結腸直腸がん（CRC）',\n",
+       " '多発性骨髄腫',\n",
+       " '固形癌',\n",
+       " '局所進行切除不能又は転移性の胃腺癌又は食道胃接合部腺癌',\n",
+       " 'IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）',\n",
+       " 'トリプルネガティブ乳がん',\n",
+       " 'EGFR遺伝子変異を有する非小細胞肺癌患者',\n",
+       " 'FGFR2遺伝子融合又は再構成を伴う胆管癌',\n",
+       " '非小細胞肺癌',\n",
+       " '多発性骨髄腫',\n",
+       " '低悪性度神経膠腫、膵癌',\n",
+       " '進行固形癌、非小細胞肺癌、頭頚部腫瘍',\n",
+       " '固形がん',\n",
+       " '卵巣癌',\n",
+       " '肝転移を有する進行又は再発固形癌の患者',\n",
+       " 'DLL3を発現する小細胞肺癌及びその他の神経内分泌腫瘍',\n",
+       " '卵巣扁平上皮癌',\n",
+       " '進行性固形がん',\n",
+       " 'BRAF V600変異を有する局所進行切除不能又は転移性黒色腫、治療歴のないBRAF V600E変異を有する転移性結...',\n",
+       " '進行又は転移性固形がん',\n",
+       " '肝細胞癌',\n",
+       " '食道がん、胃がん',\n",
+       " 'エストロゲン受容体陽性／ヒト上皮増殖因子受容体2陰性の進行乳癌',\n",
+       " 'LTK融合遺伝子陽性の進行非小細胞肺癌（NSCLC）',\n",
+       " '多発性骨髄腫患者',\n",
+       " '進行，切除不能又は転移性固形癌',\n",
+       " '食道扁平上皮癌',\n",
+       " '再発又は難治性多発性骨髄腫',\n",
+       " '固形癌',\n",
+       " 'HER2 陽性転移性結腸直腸癌',\n",
+       " '乳癌',\n",
+       " 'がん悪液質',\n",
+       " '切除不能胆道癌',\n",
+       " '進行性尿路上皮癌',\n",
+       " '多発性骨髄腫',\n",
+       " '二次性中枢神経系リンパ腫',\n",
+       " '小細胞肺癌及びその他の神経内分泌癌',\n",
+       " 'ミスマッチ修復異常を認める切除可能なStage II/III およびStage I 直腸癌',\n",
+       " '局所進行頭頸部扁平上皮癌',\n",
+       " '用量漸増コホート：固形がん\\n拡大コホート1：結腸・直腸がん\\n拡大コホート2：TMEM180陽性の結腸・直腸...',\n",
+       " '膀胱新生物受容体、線維芽細胞増殖因子',\n",
+       " '初発の多発性骨髄腫',\n",
+       " '切除不能進行・再発胃癌',\n",
+       " '非小細胞肺癌',\n",
+       " '乳房外パジェット病',\n",
+       " '頭頸部がんのがん治療に伴う口腔粘膜炎の疼痛 ',\n",
+       " '非小細胞肺癌',\n",
+       " '非小細胞肺癌',\n",
+       " '子宮体癌\\n胃癌\\n転移性去勢抵抗性前立腺癌\\n卵巣癌\\n大腸癌\\n尿路上皮癌\\n胆道癌',\n",
+       " '特定の進行固形癌',\n",
+       " '結腸・直腸癌遠隔転移の治癒切除を予定している患者',\n",
+       " '成熟B細胞性リンパ腫',\n",
+       " '非小細胞肺癌',\n",
+       " '多発性骨髄腫',\n",
+       " '再発及び／又は難治性B細胞性非ホジキンリンパ腫（B-NHL）及び再発及び／又は難治性B細胞性急性リンパ芽...',\n",
+       " '結腸直腸癌',\n",
+       " '固形がん',\n",
+       " '固形癌',\n",
+       " '・肉腫、ユーイング 、・新生物転移',\n",
+       " '進行非小細胞肺がん',\n",
+       " '乳がん',\n",
+       " '原発性直腸癌',\n",
+       " '進行非小細胞肺がん\\nEGFR変異\\nHER2変異',\n",
+       " '肝細胞癌',\n",
+       " '卵巣がん',\n",
+       " '非小細胞肺癌 ',\n",
+       " '多発性骨髄腫',\n",
+       " '悪性腹水を伴うMSS進行期消化器癌',\n",
+       " '固形がん',\n",
+       " '腹膜播種を伴う大腸癌',\n",
+       " '固形癌',\n",
+       " '標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍',\n",
+       " '進行腎細胞癌及び卵巣癌',\n",
+       " '悪性胸膜中皮腫',\n",
+       " '移植後の初発多発性骨髄腫',\n",
+       " '肝細胞癌',\n",
+       " '胃癌又は食道胃接合部癌',\n",
+       " '非小細胞肺癌',\n",
+       " '局所進行（切除不能）又は転移性乳癌',\n",
+       " '進行固形癌',\n",
+       " 'BRAF V600E 変異を有する切除可能大腸癌遠隔転移患者',\n",
+       " '進行MTAP欠損固形癌',\n",
+       " 'EGFR 遺伝子変異陽性未治療進行非小細胞肺癌',\n",
+       " '肺扁平上皮癌',\n",
+       " '標準治療がない、あるいは標準的治療法に不応又は不耐の固形癌',\n",
+       " 'Nectin-4陽性固形癌',\n",
+       " '非小���胞肺癌',\n",
+       " '胃癌、食道胃接合部癌',\n",
+       " '筋層浸潤性膀胱癌',\n",
+       " '進行固形癌',\n",
+       " '切除不能な局所進行非小細胞肺癌（ステージIII）',\n",
+       " '胃腺癌，食道胃接合部腺癌，膵腺癌',\n",
+       " '多発性骨髄腫',\n",
+       " '非小細胞肺癌を除くALK 融合遺伝子陽性、進行・再発の固形腫瘍',\n",
+       " '再発又は難治性のB細胞性非ホジキンリンパ腫',\n",
+       " 'PD-L1高発現（TPSが50%以上）の進行又は転移性非小細胞肺癌',\n",
+       " 'びまん性大細胞リンパ腫、急性リンパ芽球性白血病、慢性リンパ性白血病',\n",
+       " '乳癌、胆道癌、卵巣癌、子宮内膜癌',\n",
+       " '固形癌',\n",
+       " '進行性又は転移性の固形がん',\n",
+       " '前立腺癌',\n",
+       " 'HER2エクソン19又は20の変異を有する非小細胞肺癌',\n",
+       " '固形がん',\n",
+       " 'NRG1融合が記録されているNSCLC、膵腺癌、および他のすべての固形腫瘍',\n",
+       " '悪性胸膜中皮腫',\n",
+       " '中間期肝細胞癌',\n",
+       " '局所進行又は転移性固形がん',\n",
+       " '消化管間質腫瘍',\n",
+       " '転移性又は切除不能の悪性黒色腫, 転移性又は切除不能の肝細胞癌, 転移性又は切除不能の大腸癌',\n",
+       " '非小細胞肺癌，進行固形癌，胃食道接合部腺癌，大腸癌',\n",
+       " '肺扁平上皮癌',\n",
+       " '非小細胞肺癌（NSCLC），頭頸部扁平上皮癌（HNSCC），その他の固形癌',\n",
+       " '進行・再発非小細胞肺癌',\n",
+       " '非小細胞肺癌（NSCLC）',\n",
+       " '乳がん',\n",
+       " '中皮腫，NF2 / LATS1 / LATS2 変異を伴う腫瘍，及び機能獲得性YAP / TAZ融合を伴う腫瘍を有する患者',\n",
+       " 'HER2陽性の胃癌または胃食道接合部癌',\n",
+       " '再発悪性神経膠腫',\n",
+       " '固形癌',\n",
+       " '上皮性卵巣がん（原発性腹膜がん及び卵管がんを含む）',\n",
+       " '非小細胞肺癌、大腸新生物、子宮内膜新生物、卵巣新生物、膵臓新生物、胆道新生物',\n",
+       " '【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・HRD陽性の子宮平滑筋...',\n",
+       " '未治療の治癒切除不能な膵がん患者（ 遠隔転移例・切除不能局所進行膵がん）を対象とし、術後の再発症例...',\n",
+       " '成人のROS1 融合遺伝子陽性の進行または転移性非小細胞肺癌(NSCLC)患者',\n",
+       " '転移性食道扁平上皮癌',\n",
+       " '多発性骨髄腫',\n",
+       " '進行固形がん',\n",
+       " '再発又は難治性の多発性骨髄腫（RRMM）',\n",
+       " '胃癌',\n",
+       " '進行固形癌',\n",
+       " '・進行固形癌 \\n・KRAS p.G12C変異を有する',\n",
+       " 'LK、ROS1またはNTRK1-3の遺伝子再構成を有する進行固形癌患者',\n",
+       " '筋層非浸潤性膀胱がん',\n",
+       " '固形がん及び血液がん（AML, MDS, DLBCL）',\n",
+       " '成人 T 細胞白血病・リンパ腫',\n",
+       " 'ER陽性HER2陰性乳癌',\n",
+       " '進行固形癌',\n",
+       " '筋層浸潤性膀胱癌',\n",
+       " '進行又は転移性非小細胞肺癌',\n",
+       " '再発又は難治性の大細胞型B細胞リンパ腫',\n",
+       " 'GPC3発現手術不能進行再発卵巣明細胞癌で腹膜播種を有する患者',\n",
+       " '筋層非浸潤性膀胱癌',\n",
+       " '前立腺がん',\n",
+       " '非ホジキンリンパ腫 （びまん性大細胞型B細胞リンパ腫）',\n",
+       " '膀胱癌',\n",
+       " '表在性食道癌',\n",
+       " '多発性骨髄腫',\n",
+       " '膵臓がん',\n",
+       " '局所進行または転移性ER陽性HER2陰性乳癌，局所進行または転移性去勢抵抗性前立腺癌，局所進行または転...',\n",
+       " '頭頸部扁平上皮がん',\n",
+       " '固形癌（非小細胞肺癌など）',\n",
+       " '胃腺癌、胃食道接合部腺癌又は食道腺癌',\n",
+       " '膠芽腫',\n",
+       " '4型進行胃癌',\n",
+       " '悪性黒色腫',\n",
+       " '進行性悪性黒色腫']"
+      ]
+     },
+     "execution_count": 58,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "target_list"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 61,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "with open('test.txt', 'w') as f:\n",
+    "    print(target_list, file=f)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 70,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Target列を分割する関数\n",
+    "def split_target(target):\n",
+    "    # 指定された区切り文字で分割\n",
+    "    split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n",
+    "    # 空白文字を除外してリストとして返す\n",
+    "    return [word.strip() for word in split_words if word.strip()]"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 73,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/plain": [
+       "['PD-L1高発現（TPSが50%以上）の進行', '転移性非小細胞肺癌', '神経膠腫']"
+      ]
+     },
+     "execution_count": 73,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "split_target('PD-L1高発現（TPSが50%以上）の進行・転移性非小細胞肺癌、神経膠腫')"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 74,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Target列を分割してTargetWord列を追加\n",
+    "basedf['TargetWord'] = basedf['Target'].apply(split_target)\n"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 75,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>JRCT ID</th>\n",
+       "      <th>NCT No</th>\n",
+       "      <th>JapicCTI No</th>\n",
+       "      <th>Title</th>\n",
+       "      <th>Target</th>\n",
+       "      <th>研究・治験の目的</th>\n",
+       "      <th>試験等のフェーズ</th>\n",
+       "      <th>試験の種類</th>\n",
+       "      <th>無作為化</th>\n",
+       "      <th>盲検化</th>\n",
+       "      <th>...</th>\n",
+       "      <th>purpose</th>\n",
+       "      <th>Inclusion Criteria</th>\n",
+       "      <th>Exclusion Criteria</th>\n",
+       "      <th>Age Minimum</th>\n",
+       "      <th>Age Maximum</th>\n",
+       "      <th>Gender</th>\n",
+       "      <th>Discontinuation Criteria</th>\n",
+       "      <th>Keyword</th>\n",
+       "      <th>Intervention(s)</th>\n",
+       "      <th>TargetWord</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>jRCT2021240039</td>\n",
+       "      <td>NCT06632951</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>[M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal...</td>\n",
+       "      <td>尿路上皮癌</td>\n",
+       "      <td>主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Participant has histologically or cytological...</td>\n",
+       "      <td>-Participant has received more than 1 prior ch...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r...</td>\n",
+       "      <td>[尿路上皮癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>4</th>\n",
+       "      <td>jRCT2031240512</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>フッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌...</td>\n",
+       "      <td>切除不能進行・再発胃癌</td>\n",
+       "      <td>フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor...</td>\n",
+       "      <td>1)\\tPrior treatment history with paclitaxel, r...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>75age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Safety Part (Dose Escalation):\\r\\nLevel 0: Bev...</td>\n",
+       "      <td>[切除不能進行, 再発胃癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>7</th>\n",
+       "      <td>jRCT2051240197</td>\n",
+       "      <td>NCT06692738</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>PD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto...</td>\n",
+       "      <td>非小細胞肺癌</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>二重盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Histologically or cytologically documented s...</td>\n",
+       "      <td>- Presence of small cell and neuroendocrine hi...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Participants will be randomized in a 1:1 ratio...</td>\n",
+       "      <td>[非小細胞肺癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>8</th>\n",
+       "      <td>jRCT2031240508</td>\n",
+       "      <td>NCT06573294</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用...</td>\n",
+       "      <td>進行性悪性固形癌\\n転移性悪性固形癌</td>\n",
+       "      <td>本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Advanced and/or metastatic solid tumors, who ...</td>\n",
+       "      <td>Has been exposed to any of the following prior...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>GEN1057 monotherapy will be administered intra...</td>\n",
+       "      <td>[進行性悪性固形癌, 転移性悪性固形癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>12</th>\n",
+       "      <td>jRCT2041240130</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...</td>\n",
+       "      <td>肺がん</td>\n",
+       "      <td>全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(1) Patients scheduled to undergo anatomical l...</td>\n",
+       "      <td>(1) Patients with a history of allergy to the ...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Treatment group\\r\\nAdminister GRA 1mg intraven...</td>\n",
+       "      <td>[肺がん]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>...</th>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>974</th>\n",
+       "      <td>jRCT2031200203</td>\n",
+       "      <td>NCT04379596</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>HER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法...</td>\n",
+       "      <td>胃腺癌、胃食道接合部腺癌又は食道腺癌</td>\n",
+       "      <td>DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Male and female participants must be at lea...</td>\n",
+       "      <td>1. History of active primary immunodeficiency,...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>130age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Experimental: Arm 1A: T-DXd and 5-fluorouracil...</td>\n",
+       "      <td>[胃腺癌, 胃食道接合部腺癌, 食道腺癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>981</th>\n",
+       "      <td>jRCT2031200153</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Cellm-001による初発膠芽腫治療効果無作為比較対照試験</td>\n",
+       "      <td>膠芽腫</td>\n",
+       "      <td>脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>二重盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(1) 18 years old or older and 75 years old or ...</td>\n",
+       "      <td>(1) Systemic administration of corticosteroids...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>75age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Inject the investigational drug (Cellm-001 or ...</td>\n",
+       "      <td>[膠芽腫]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>996</th>\n",
+       "      <td>jRCT2031200087</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療...</td>\n",
+       "      <td>4型進行胃癌</td>\n",
+       "      <td>術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Confirmation before temporary registration\\r\\n...</td>\n",
+       "      <td>1)\\tSimultaneously active double cancer.\\r\\n2)...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>75age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>S-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da...</td>\n",
+       "      <td>[4型進行胃癌]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>1053</th>\n",
+       "      <td>jRCT2033190086</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...</td>\n",
+       "      <td>悪性黒色腫</td>\n",
+       "      <td>第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>単一群</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(Phase 1)\\r\\n1) Histologically confirmed malig...</td>\n",
+       "      <td>(Phase 1 and 2)\\r\\n1) Patients who have brain ...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>malignamt  melanoma, advanced stage</td>\n",
+       "      <td>Test drug (T-hIL12) will be administered into ...</td>\n",
+       "      <td>[悪性黒色腫]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>1067</th>\n",
+       "      <td>jRCT2051190009</td>\n",
+       "      <td>NCT03818893</td>\n",
+       "      <td>JapicCTI-194618</td>\n",
+       "      <td>進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...</td>\n",
+       "      <td>進行性悪性黒色腫</td>\n",
+       "      <td>抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>非無作為化比較</td>\n",
+       "      <td>非盲検</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Inclusion criteria \\r\\nPatients meeting all of...</td>\n",
+       "      <td>Exclusion criteria\\r\\nPatients meeting any of ...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>86age old not</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>advanced melanoma</td>\n",
+       "      <td>combination therapy of intracutaneous GEN0101 ...</td>\n",
+       "      <td>[進行性悪性黒色腫]</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>416 rows × 39 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "             JRCT ID       NCT No      JapicCTI No  \\\n",
+       "0     jRCT2021240039  NCT06632951              NaN   \n",
+       "4     jRCT2031240512          NaN              NaN   \n",
+       "7     jRCT2051240197  NCT06692738              NaN   \n",
+       "8     jRCT2031240508  NCT06573294              NaN   \n",
+       "12    jRCT2041240130          NaN              NaN   \n",
+       "...              ...          ...              ...   \n",
+       "974   jRCT2031200203  NCT04379596              NaN   \n",
+       "981   jRCT2031200153          NaN              NaN   \n",
+       "996   jRCT2031200087          NaN              NaN   \n",
+       "1053  jRCT2033190086          NaN              NaN   \n",
+       "1067  jRCT2051190009  NCT03818893  JapicCTI-194618   \n",
+       "\n",
+       "                                                  Title              Target  \\\n",
+       "0     [M25-204]転移性尿路上皮癌患者を対象に，livmoniplimab とbudigal...               尿路上皮癌   \n",
+       "4     フッ化ピリミジン製剤及びプラチナ製剤を含む一次治療に不応・不耐となった切除不能進行・再発胃癌...         切除不能進行・再発胃癌   \n",
+       "7     PD-L1 陽性の転移性扁平上皮非小細胞肺癌患者に対する一次治療として、Rilvegosto...              非小細胞肺癌   \n",
+       "8     悪性固形癌患者を対象にGEN1057の安全性及び抗腫瘍活性を評価するヒト初回投与、非盲検、用...  進行性悪性固形癌\\n転移性悪性固形癌   \n",
+       "12    中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...                 肺がん   \n",
+       "...                                                 ...                 ...   \n",
+       "974   HER2発現の成人胃癌患者を対象としてトラスツズマブ デルクステカン（T-DXd）の単剤療法...  胃腺癌、胃食道接合部腺癌又は食道腺癌   \n",
+       "981                      Cellm-001による初発膠芽腫治療効果無作為比較対照試験                 膠芽腫   \n",
+       "996   4型進行胃癌に対する術後または周術期補助化学療法としての全身・腹腔内併用化学療法と全身化学療...              4型進行胃癌   \n",
+       "1053  悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...               悪性黒色腫   \n",
+       "1067  進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...            進行性悪性黒色腫   \n",
+       "\n",
+       "                                               研究・治験の目的 試験等のフェーズ 試験の種類  \\\n",
+       "0     主要目的：全生存期間（以下「OS」）を指標として，livmoniplimab と budig...        2   NaN   \n",
+       "4     フッ化ピリミジン・プラチナ系薬剤に不応・不耐の切除不能進行・再発胃癌被験者を対象として、ベバ...        1   NaN   \n",
+       "7                                             Treatment        3   NaN   \n",
+       "8     本第I相試験の目的は、転移性又は進行性病変を有する悪性固形癌患者を対象に、GEN1057を単...        1   NaN   \n",
+       "12    全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...        2   NaN   \n",
+       "...                                                 ...      ...   ...   \n",
+       "974   DESTINY-Gastric03は、HER2発現の進行・転移性胃癌・胃食道接合部（GEJ）...      1-2   NaN   \n",
+       "981   脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...        3   NaN   \n",
+       "996   術後腹膜播種のリスクが高い4型進行胃癌を対象として、全身・腹腔内併用化学療法の全身化学療法に...        3   NaN   \n",
+       "1053  第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...      1-2   NaN   \n",
+       "1067  抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...      1-2   NaN   \n",
+       "\n",
+       "         無作為化   盲検化  ...            purpose  \\\n",
+       "0      無作為化比較   非盲検  ...  treatment purpose   \n",
+       "4      無作為化比較   非盲��  ...  treatment purpose   \n",
+       "7      無作為化比較  二重盲検  ...  treatment purpose   \n",
+       "8         単一群   非盲検  ...  treatment purpose   \n",
+       "12     無作為化比較   非盲検  ...  treatment purpose   \n",
+       "...       ...   ...  ...                ...   \n",
+       "974    無作為化比較   非盲検  ...  treatment purpose   \n",
+       "981    無作為化比較  二重盲検  ...  treatment purpose   \n",
+       "996    無作為化比較   非盲検  ...  treatment purpose   \n",
+       "1053      単一群   非盲検  ...  treatment purpose   \n",
+       "1067  非無作為化比較   非盲検  ...  treatment purpose   \n",
+       "\n",
+       "                                     Inclusion Criteria  \\\n",
+       "0     -Participant has histologically or cytological...   \n",
+       "4     1)\\tAge between 18 and 75 years.\\r\\n2)\\tPerfor...   \n",
+       "7     - Histologically or cytologically documented s...   \n",
+       "8     -Advanced and/or metastatic solid tumors, who ...   \n",
+       "12    (1) Patients scheduled to undergo anatomical l...   \n",
+       "...                                                 ...   \n",
+       "974   1. Male and female participants must be at lea...   \n",
+       "981   (1) 18 years old or older and 75 years old or ...   \n",
+       "996   Confirmation before temporary registration\\r\\n...   \n",
+       "1053  (Phase 1)\\r\\n1) Histologically confirmed malig...   \n",
+       "1067  Inclusion criteria \\r\\nPatients meeting all of...   \n",
+       "\n",
+       "                                     Exclusion Criteria     Age Minimum  \\\n",
+       "0     -Participant has received more than 1 prior ch...  18age old over   \n",
+       "4     1)\\tPrior treatment history with paclitaxel, r...  18age old over   \n",
+       "7     - Presence of small cell and neuroendocrine hi...  18age old over   \n",
+       "8     Has been exposed to any of the following prior...  18age old over   \n",
+       "12    (1) Patients with a history of allergy to the ...  18age old over   \n",
+       "...                                                 ...             ...   \n",
+       "974   1. History of active primary immunodeficiency,...  18age old over   \n",
+       "981   (1) Systemic administration of corticosteroids...  18age old over   \n",
+       "996   1)\\tSimultaneously active double cancer.\\r\\n2)...  20age old over   \n",
+       "1053  (Phase 1 and 2)\\r\\n1) Patients who have brain ...  20age old over   \n",
+       "1067  Exclusion criteria\\r\\nPatients meeting any of ...  20age old over   \n",
+       "\n",
+       "           Age Maximum Gender Discontinuation Criteria  \\\n",
+       "0             No limit   Both                      NaN   \n",
+       "4      75age old under   Both                      NaN   \n",
+       "7             No limit   Both                      NaN   \n",
+       "8             No limit   Both                      NaN   \n",
+       "12            No limit   Both                      NaN   \n",
+       "...                ...    ...                      ...   \n",
+       "974   130age old under   Both                      NaN   \n",
+       "981    75age old under   Both                      NaN   \n",
+       "996    75age old under   Both                      NaN   \n",
+       "1053          No limit   Both                      NaN   \n",
+       "1067     86age old not   Both                      NaN   \n",
+       "\n",
+       "                                  Keyword  \\\n",
+       "0                                     NaN   \n",
+       "4                                     NaN   \n",
+       "7                                     NaN   \n",
+       "8                                     NaN   \n",
+       "12                                    NaN   \n",
+       "...                                   ...   \n",
+       "974                                   NaN   \n",
+       "981                                   NaN   \n",
+       "996                                   NaN   \n",
+       "1053  malignamt  melanoma, advanced stage   \n",
+       "1067                    advanced melanoma   \n",
+       "\n",
+       "                                        Intervention(s)             TargetWord  \n",
+       "0     -Arm 1: Livmoniplimab (Dose A) + Budigalimab\\r...                [尿路上皮癌]  \n",
+       "4     Safety Part (Dose Escalation):\\r\\nLevel 0: Bev...         [切除不能進行, 再発胃癌]  \n",
+       "7     Participants will be randomized in a 1:1 ratio...               [非小細胞肺癌]  \n",
+       "8     GEN1057 monotherapy will be administered intra...   [進行性悪性固形癌, 転移性悪性固形癌]  \n",
+       "12    Treatment group\\r\\nAdminister GRA 1mg intraven...                  [肺がん]  \n",
+       "...                                                 ...                    ...  \n",
+       "974   Experimental: Arm 1A: T-DXd and 5-fluorouracil...  [胃腺癌, 胃食道接合部腺癌, ��道腺癌]  \n",
+       "981   Inject the investigational drug (Cellm-001 or ...                  [膠芽腫]  \n",
+       "996   S-1 monotherapy\\r\\noral S-1 80 mg/m2/day on da...               [4型進行胃癌]  \n",
+       "1053  Test drug (T-hIL12) will be administered into ...                [悪性黒色腫]  \n",
+       "1067  combination therapy of intracutaneous GEN0101 ...             [進行性悪性黒色腫]  \n",
+       "\n",
+       "[416 rows x 39 columns]"
+      ]
+     },
+     "execution_count": 75,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "basedf"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": null,
+   "metadata": {},
+   "outputs": [],
+   "source": []
+  }
+ ],
+ "metadata": {
+  "kernelspec": {
+   "display_name": "gradio",
+   "language": "python",
+   "name": "python3"
+  },
+  "language_info": {
+   "codemirror_mode": {
+    "name": "ipython",
+    "version": 3
+   },
+   "file_extension": ".py",
+   "mimetype": "text/x-python",
+   "name": "python",
+   "nbconvert_exporter": "python",
+   "pygments_lexer": "ipython3",
+   "version": "3.12.3"
+  }
+ },
+ "nbformat": 4,
+ "nbformat_minor": 2
+}